Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) has caught the attention of institutional investors who hold a sizeable 46% stake

In This Article:

Key Insights

  • Institutions' substantial holdings in Eledon Pharmaceuticals implies that they have significant influence over the company's share price

  • The top 13 shareholders own 51% of the company

  • Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

To get a sense of who is truly in control of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), it is important to understand the ownership structure of the business. And the group that holds the biggest piece of the pie are institutions with 46% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future.

Let's delve deeper into each type of owner of Eledon Pharmaceuticals, beginning with the chart below.

See our latest analysis for Eledon Pharmaceuticals

ownership-breakdown
NasdaqCM:ELDN Ownership Breakdown May 2nd 2025

What Does The Institutional Ownership Tell Us About Eledon Pharmaceuticals?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

As you can see, institutional investors have a fair amount of stake in Eledon Pharmaceuticals. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Eledon Pharmaceuticals, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
NasdaqCM:ELDN Earnings and Revenue Growth May 2nd 2025

Our data indicates that hedge funds own 16% of Eledon Pharmaceuticals. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. BVF Partners L.P. is currently the company's largest shareholder with 11% of shares outstanding. With 6.0% and 5.2% of the shares outstanding respectively, RA Capital Management, L.P. and Armistice Capital LLC are the second and third largest shareholders.